170 related articles for article (PubMed ID: 3882856)
21. Antibody response to bacterial antigens covalently bound to biodegradable polymerized serum albumin beads.
Langhein C; Newman JF
J Appl Bacteriol; 1987 Nov; 63(5):443-8. PubMed ID: 3326866
[TBL] [Abstract][Full Text] [Related]
22. A Semi-Synthetic Glycoconjugate Vaccine Candidate for Carbapenem-Resistant Klebsiella pneumoniae.
Seeberger PH; Pereira CL; Khan N; Xiao G; Diago-Navarro E; Reppe K; Opitz B; Fries BC; Witzenrath M
Angew Chem Int Ed Engl; 2017 Nov; 56(45):13973-13978. PubMed ID: 28815890
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of phagocytic-resistant capsular serotypes of Klebsiella pneumoniae in liver abscess.
Lin JC; Chang FY; Fung CP; Xu JZ; Cheng HP; Wang JJ; Huang LY; Siu LK
Microbes Infect; 2004 Nov; 6(13):1191-8. PubMed ID: 15488738
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.
Edelman R; Taylor DN; Wasserman SS; McClain JB; Cross AS; Sadoff JC; Que JU; Cryz SJ
Vaccine; 1994 Nov; 12(14):1288-94. PubMed ID: 7856293
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of immunoprotection against fatal experimental Klebsiella pneumoniae pneumonia].
Shimoguchi K
Kansenshogaku Zasshi; 1990 Dec; 64(12):1482-92. PubMed ID: 2074365
[TBL] [Abstract][Full Text] [Related]
26. Immunoprotective extracellular polysaccharides of Klebsiella aerogenes capsular type K1, expressed in Escherichia coli.
Roe EA; Jones RJ; Saunders JR
FEMS Microbiol Immunol; 1989 Apr; 1(5):253-61. PubMed ID: 2517220
[TBL] [Abstract][Full Text] [Related]
27. Resistance to Klebsiella pneumoniae and the importance of two bacterial antigens.
Cooper JM; Rowley D
Aust J Exp Biol Med Sci; 1982 Dec; 60(6):629-41. PubMed ID: 6820634
[TBL] [Abstract][Full Text] [Related]
28. Direct evidence for the involvement of capsular polysaccharide in the immunoprotective activity of Klebsiella pneumoniae ribosomal preparations.
Riottot MM; Fournier JM; Jouin H
Infect Immun; 1981 Jan; 31(1):71-7. PubMed ID: 7012008
[TBL] [Abstract][Full Text] [Related]
29. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
30. A murine monoclonal antibody against Klebsiella capsular polysaccharide is opsonic in vitro and protects against experimental Klebsiella pneumoniae infection.
Trautmann M; Cryz SJ; Sadoff JC; Cross AS
Microb Pathog; 1988 Sep; 5(3):177-87. PubMed ID: 3063912
[TBL] [Abstract][Full Text] [Related]
31. Immunization with the outer membrane proteins OmpK17 and OmpK36 elicits protection against Klebsiella pneumoniae in the murine infection model.
Hussein KE; Bahey-El-Din M; Sheweita SA
Microb Pathog; 2018 Jun; 119():12-18. PubMed ID: 29626658
[TBL] [Abstract][Full Text] [Related]
32. Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa.
Hegerle N; Choi M; Sinclair J; Amin MN; Ollivault-Shiflett M; Curtis B; Laufer RS; Shridhar S; Brammer J; Toapanta FR; Holder IA; Pasetti MF; Lees A; Tennant SM; Cross AS; Simon R
PLoS One; 2018; 13(9):e0203143. PubMed ID: 30188914
[TBL] [Abstract][Full Text] [Related]
33. Passive immunization of mice against Klebsiella aerogenes.
Roe EA; Jones RJ; Dyster RE
Br J Exp Pathol; 1986 Feb; 67(1):25-32. PubMed ID: 3511939
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody against Klebsiella capsular polysaccharide reduces severity and hematogenic spread of experimental Klebsiella pneumoniae pneumonia.
Held TK; Trautmann M; Mielke ME; Neudeck H; Cryz SJ; Cross AS
Infect Immun; 1992 May; 60(5):1771-8. PubMed ID: 1563764
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
[TBL] [Abstract][Full Text] [Related]
36. Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development.
Cryz SJ; Mortimer PM; Mansfield V; Germanier R
J Clin Microbiol; 1986 Apr; 23(4):687-90. PubMed ID: 3517058
[TBL] [Abstract][Full Text] [Related]
37. Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections.
Clements A; Jenney AW; Farn JL; Brown LE; Deliyannis G; Hartland EL; Pearse MJ; Maloney MB; Wesselingh SL; Wijburg OL; Strugnell RA
Vaccine; 2008 Oct; 26(44):5649-53. PubMed ID: 18725260
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant action of capsular polysaccharide of Klebsiella pneumoniae on antibody response. VIII. Its effect on the size and the number of cells of regional lymph node and other lymphoid organs.
Yokochi T; Nakashima I; Kato N
Microbiol Immunol; 1980; 24(2):141-54. PubMed ID: 6991886
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
Kim YR; Yoo JH; Hur JK; Kang JH; Shin WS; Kang MW
J Korean Med Sci; 1995 Oct; 10(5):314-7. PubMed ID: 8750055
[TBL] [Abstract][Full Text] [Related]
40. Antibody-Based Immunotherapy To Treat and Prevent Infection with Hypervirulent Klebsiella pneumoniae.
Diago-Navarro E; Calatayud-Baselga I; Sun D; Khairallah C; Mann I; Ulacia-Hernando A; Sheridan B; Shi M; Fries BC
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
